NCT05759325Not yet recruiting
An Exploratory Study of ctDNA-MRD in Predicting the Efficacy of Esophageal Squamous Cell Carcinoma
Application of ctDNA-MRD in the Prediction of Curative Effect, Recurrence Monitoring and Prognosis Evaluation of Esophageal Squamous Cell Carcinoma (ESCC) During Perioperative Treatment
Source: ClinicalTrials.gov · Last updated 8 Mar 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The purpose of this study is to observe and evaluate the correlation between ctDNA-MRD and the therapeutic effect and prognosis of stage II-IVA operable esophageal squamous cell carcinoma.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 25 Feb 2023
- Start date
- Mar 2023
- Primary completion date
- Mar 2026
- Lead sponsor
- Guangzhou Institute of Respiratory Disease
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT05759325
What you commit to
- Study type: Observational
- Planned participants: 100
- From Mar 2023 to the primary completion date, Mar 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patient had undergone surgery before admission;
- Patients with contraindications to radiotherapy and chemotherapy;
Other illness
- Patients with other malignant tumors;
- Patients with other serious diseases;
Other
- Pregnant or lactating women;
- Patients who could not understand the experiment content and could not cooperate with them and refused to sign the informed consent form;
- Other researchers think it is not suitable.
Who the study is looking for
- Patients with stage II-IVA Esophageal squamous cell carcinoma confirmed by clinical pathological staging;
- ≥18 years;
- Eastern Cooperative Oncology Group performance status score (ECOG PS) is 0 \~ 1 points;
- Expected survival time ≥ 6 months;
- Patients agree and have the ability to follow the planned study visits, laboratory tests and other research steps.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.